Fulgent Genetics, Inc. (FLGT) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2022
Loading P/E history...
FLGT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Fulgent Genetics, Inc. (FLGT) trades at a price-to-earnings ratio of -7.7x, with a stock price of $15.11 and trailing twelve-month earnings per share of $-1.97.
The current P/E is 141% below its 5-year average of 18.9x. Over the past five years, FLGT's P/E has ranged from a low of 4.2x to a high of 139.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, FLGT trades at a 134% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, FLGT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our FLGT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
FLGT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $21B | 24.7 | - | +18% | |
| $21B | 21.8Lowest | - | +14% | |
| $7B | 56.8 | 3.40Best | +311%Best | |
| $2B | 29.5 | 4.40 | +14% | |
| $21B | 25.5 | 6.01 | +171% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
FLGT Historical P/E Data (2020–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $29.78 | $4.56 | 6.5x | -65% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $38.12 | $8.70 | 4.4x | -77% |
| FY2022 Q2 | $54.53 | $12.57 | 4.3x | -77% | |
| FY2022 Q1 | $62.41 | $14.79 | 4.2x | -78% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $100.59 | $16.38 | 6.1x | -68% |
| FY2021 Q3 | $89.95 | $19.20 | 4.7x | -75% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $92.23 | $17.25 | 5.3x | -72% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $96.62 | $14.80 | 6.5x | -65% |
| FY2020 Q4 | $52.10 | $8.19 | 6.4x | -66% | |
| FY2020 Q3 | Wed Sep 30 2020 00:00:00 GM | $40.04 | $2.01 | 19.9x | +5% |
| FY2020 Q2 | $16.00 | $0.11 | 139.7x | +638% |
Average P/E for displayed period: 18.9x
See FLGT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FLGT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FLGT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFLGT — Frequently Asked Questions
Quick answers to the most common questions about buying FLGT stock.
Is FLGT stock overvalued or undervalued?
FLGT trades at -7.7x P/E, below its 5-year average of 18.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does FLGT's valuation compare to peers?
Fulgent Genetics, Inc. P/E of -7.7x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is FLGT's PEG ratio?
FLGT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2022.